Strides Shasun shares rise over 5% on USFDA approval for new drug
New Delhi: Shares of Strides Shasun rose by over 5 per cent after the company's subsidiary Strides Pharma Global received final approval from the US health regulator for generic Oseltamivir Phosphate capsules.
The stock gained 3.83 per cent to close at Rs 363.05 on BSE. During the day, it jumped 5.53 per cent to Rs 369.
At NSE, shares of the company rose by 5.28 per cent to end at Rs 368.30.
In terms of equity volume, 12.39 lakh shares of the firm were traded on BSE and over one crore shares changed hands at NSE during the day.
Strides Pharma Global Pte has received approval from the US Food and Drug Administration (USFDA) for the capsules in the strengths of 30 mg (base), 45 mg (base) and 75 mg (base), Strides Shasun said in a BSE filing yesterday.
The product is a generic version of Hoffmann-La Roche Inc's Tamiflu capsules, it added.
The stock gained 3.83 per cent to close at Rs 363.05 on BSE. During the day, it jumped 5.53 per cent to Rs 369.
At NSE, shares of the company rose by 5.28 per cent to end at Rs 368.30.
In terms of equity volume, 12.39 lakh shares of the firm were traded on BSE and over one crore shares changed hands at NSE during the day.
Strides Pharma Global Pte has received approval from the US Food and Drug Administration (USFDA) for the capsules in the strengths of 30 mg (base), 45 mg (base) and 75 mg (base), Strides Shasun said in a BSE filing yesterday.
The product is a generic version of Hoffmann-La Roche Inc's Tamiflu capsules, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd